Drug-induced liver disease (DILI)

Julie Polson, Naga Chalasani

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

BACKGROUND Hepatotoxicity is among the most common and feared adverse drug reactions. Television commercials advertising pharmaceuticals warn patients to beware of taking various medications if they have liver disease. Lawyers publicly recruit business from patients or loved ones of patients who may have had a hepatotoxic drug reaction; there were several newspaper ads placed by law firms after troglitazone was removed from the market, for example. Clinicians are wary of prescribing medications described to have potential adverse effects on the liver without frequent monitoring of liver tests or referral to a hepatologist. In fact, hepatotoxicity is the most common single adverse drug reaction leading to drug withdrawal and refusal for FDA approval. For hepatologists and primary care physicians alike, drug hepatotoxicity is a tough clinical problem because it is a diagnosis of exclusion, may be difficult to diagnose, and there is no clear treatment other than drug withdrawal in many cases. From a public health standpoint, the difficulty in studying and predicting hepatotoxic drug reactions in a few patients may prevent thousands from receiving medications that would be beneficial to them. In short, drug-induced liver injury (DILI) is a complicated and of ten confusing entity that can pose problems for patients and the practitioners who care for them. In this article, we will provide an overview of idiosyncratic DILI with relatively minor focus on acetaminophen hepatotoxicity. EPIDEMIOLOGY The true incidence of idiosyncratic DILI is unknown. The difficulty of correctly establishing the diagnosis as well as underreporting to regulatory agencies makes determining disease frequency problematic.

Original languageEnglish (US)
Title of host publicationPractical Management of Liver Diseases
PublisherCambridge University Press
Pages174-194
Number of pages21
ISBN (Print)9780511547416, 9780521684897
DOIs
StatePublished - Jan 1 2008

Fingerprint

Chemical and Drug Induced Liver Injury
Pharmaceutical Preparations
troglitazone
Drug-Related Side Effects and Adverse Reactions
Lawyers
Newspapers
Liver
Television
Primary Care Physicians
Acetaminophen
Liver Diseases
Referral and Consultation
Public Health
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Polson, J., & Chalasani, N. (2008). Drug-induced liver disease (DILI). In Practical Management of Liver Diseases (pp. 174-194). Cambridge University Press. https://doi.org/10.1017/CBO9780511547416.012

Drug-induced liver disease (DILI). / Polson, Julie; Chalasani, Naga.

Practical Management of Liver Diseases. Cambridge University Press, 2008. p. 174-194.

Research output: Chapter in Book/Report/Conference proceedingChapter

Polson, J & Chalasani, N 2008, Drug-induced liver disease (DILI). in Practical Management of Liver Diseases. Cambridge University Press, pp. 174-194. https://doi.org/10.1017/CBO9780511547416.012
Polson J, Chalasani N. Drug-induced liver disease (DILI). In Practical Management of Liver Diseases. Cambridge University Press. 2008. p. 174-194 https://doi.org/10.1017/CBO9780511547416.012
Polson, Julie ; Chalasani, Naga. / Drug-induced liver disease (DILI). Practical Management of Liver Diseases. Cambridge University Press, 2008. pp. 174-194
@inbook{779dd7ff8c35413d9e26ebeb10354535,
title = "Drug-induced liver disease (DILI)",
abstract = "BACKGROUND Hepatotoxicity is among the most common and feared adverse drug reactions. Television commercials advertising pharmaceuticals warn patients to beware of taking various medications if they have liver disease. Lawyers publicly recruit business from patients or loved ones of patients who may have had a hepatotoxic drug reaction; there were several newspaper ads placed by law firms after troglitazone was removed from the market, for example. Clinicians are wary of prescribing medications described to have potential adverse effects on the liver without frequent monitoring of liver tests or referral to a hepatologist. In fact, hepatotoxicity is the most common single adverse drug reaction leading to drug withdrawal and refusal for FDA approval. For hepatologists and primary care physicians alike, drug hepatotoxicity is a tough clinical problem because it is a diagnosis of exclusion, may be difficult to diagnose, and there is no clear treatment other than drug withdrawal in many cases. From a public health standpoint, the difficulty in studying and predicting hepatotoxic drug reactions in a few patients may prevent thousands from receiving medications that would be beneficial to them. In short, drug-induced liver injury (DILI) is a complicated and of ten confusing entity that can pose problems for patients and the practitioners who care for them. In this article, we will provide an overview of idiosyncratic DILI with relatively minor focus on acetaminophen hepatotoxicity. EPIDEMIOLOGY The true incidence of idiosyncratic DILI is unknown. The difficulty of correctly establishing the diagnosis as well as underreporting to regulatory agencies makes determining disease frequency problematic.",
author = "Julie Polson and Naga Chalasani",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511547416.012",
language = "English (US)",
isbn = "9780511547416",
pages = "174--194",
booktitle = "Practical Management of Liver Diseases",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Drug-induced liver disease (DILI)

AU - Polson, Julie

AU - Chalasani, Naga

PY - 2008/1/1

Y1 - 2008/1/1

N2 - BACKGROUND Hepatotoxicity is among the most common and feared adverse drug reactions. Television commercials advertising pharmaceuticals warn patients to beware of taking various medications if they have liver disease. Lawyers publicly recruit business from patients or loved ones of patients who may have had a hepatotoxic drug reaction; there were several newspaper ads placed by law firms after troglitazone was removed from the market, for example. Clinicians are wary of prescribing medications described to have potential adverse effects on the liver without frequent monitoring of liver tests or referral to a hepatologist. In fact, hepatotoxicity is the most common single adverse drug reaction leading to drug withdrawal and refusal for FDA approval. For hepatologists and primary care physicians alike, drug hepatotoxicity is a tough clinical problem because it is a diagnosis of exclusion, may be difficult to diagnose, and there is no clear treatment other than drug withdrawal in many cases. From a public health standpoint, the difficulty in studying and predicting hepatotoxic drug reactions in a few patients may prevent thousands from receiving medications that would be beneficial to them. In short, drug-induced liver injury (DILI) is a complicated and of ten confusing entity that can pose problems for patients and the practitioners who care for them. In this article, we will provide an overview of idiosyncratic DILI with relatively minor focus on acetaminophen hepatotoxicity. EPIDEMIOLOGY The true incidence of idiosyncratic DILI is unknown. The difficulty of correctly establishing the diagnosis as well as underreporting to regulatory agencies makes determining disease frequency problematic.

AB - BACKGROUND Hepatotoxicity is among the most common and feared adverse drug reactions. Television commercials advertising pharmaceuticals warn patients to beware of taking various medications if they have liver disease. Lawyers publicly recruit business from patients or loved ones of patients who may have had a hepatotoxic drug reaction; there were several newspaper ads placed by law firms after troglitazone was removed from the market, for example. Clinicians are wary of prescribing medications described to have potential adverse effects on the liver without frequent monitoring of liver tests or referral to a hepatologist. In fact, hepatotoxicity is the most common single adverse drug reaction leading to drug withdrawal and refusal for FDA approval. For hepatologists and primary care physicians alike, drug hepatotoxicity is a tough clinical problem because it is a diagnosis of exclusion, may be difficult to diagnose, and there is no clear treatment other than drug withdrawal in many cases. From a public health standpoint, the difficulty in studying and predicting hepatotoxic drug reactions in a few patients may prevent thousands from receiving medications that would be beneficial to them. In short, drug-induced liver injury (DILI) is a complicated and of ten confusing entity that can pose problems for patients and the practitioners who care for them. In this article, we will provide an overview of idiosyncratic DILI with relatively minor focus on acetaminophen hepatotoxicity. EPIDEMIOLOGY The true incidence of idiosyncratic DILI is unknown. The difficulty of correctly establishing the diagnosis as well as underreporting to regulatory agencies makes determining disease frequency problematic.

UR - http://www.scopus.com/inward/record.url?scp=84927956195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927956195&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511547416.012

DO - 10.1017/CBO9780511547416.012

M3 - Chapter

AN - SCOPUS:84927956195

SN - 9780511547416

SN - 9780521684897

SP - 174

EP - 194

BT - Practical Management of Liver Diseases

PB - Cambridge University Press

ER -